Brief: Cyxone Announces Strategic Intent To Position Its Drug Candidate T20K In MS As Prophylactic Agent

Cyxone AB

20/03/2019 09:08

March 20 (Reuters) - Cyxone AB  CYXO.ST :
    * CYXONE ANNOUNCES STRATEGIC INTENT TO POSITION ITS DRUG
CANDIDATE
T20K IN MS AS A PROPHYLACTIC AGENT
    * PRECLINICAL FINDINGS SUPPORT POSITIONING OF ITS DRUG
CANDIDATE
T20K AS A PROPHYLACTIC AGENT FOR TREATMENT OF MULTIPLE SCLEROSIS
    * SUBSTANCE COULD BE USED TO MITIGATE OR PREVENT MS EPISODES
AND
POTENTIALLY EVEN DELAY DISEASE PROGRESSION.
    * APPLICATION TO START CLINICAL TRIAL WILL BE SUBMITTED
DURING Q2
OF 2019

Source text for Eikon:  ID:nWkr3qbgRN 
Further company coverage:  CYXO.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))